Amgen and UCB have re-filed for FDA approval of osteoporosis drug romosozumab one year after the agency rejected a submission on safety grounds. The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile.
Romosozumab looked well set to come to market when it aced its first phase 3 in September 2016. That changed in May 2017 when a second phase 3 detected a new cardiovascular safety signal. Two months later, the FDA rejected a filing for approval of romosozumab in postmenopausal women with osteoporosis.
Now, Amgen and UCB have gone back to the FDA. The new filing features data from the original, 7,180-person person phase 3 trial that formed the backbone of the original submission, plus results from two other studies.
One of the other studies is the second phase 3 of romosozumab in 4,093 postmenopausal women with osteoporosis who experienced a fracture. That clinical trial found romosozumab was better than alendronate at reducing fractures but also uncovered the safety signal. The third set of data included in the filing comes from a 245 person study of the effect of romosozumab in men.
Amgen and UCB are hoping that when the FDA gets to analyze all the safety and efficacy data it will conclude the benefits of romosozumab outweigh the risks. However, there remains a chance the FDA will turn the drug down or impose a restrictive label that limits its commercial prospects.
A restrictive label could see romosozumab struggle to live up to the blockbuster forecasts made by analysts prior to the safety scare. If romosozumab comes to market, it will face competition from Eli Lilly’s Forteo and Radius Health’s Tymlos. Romosozumab has some advantages over the competition, such as monthly dosing, but these could be swept away by cardiovascular safety concerns.
By: Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
